Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 1;26(15):7413.
doi: 10.3390/ijms26157413.

Variations in Circulating Tumor Microenvironment-Associated Proteins in Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C Treatment

Benito Blanco Gómez  1 , Francisco Javier Casas-Nebra  1 , Daniel Pérez-Fentes  2 , Susana B Bravo  3 , Laura Rodríguez-Silva  4 , Cristina Núñez  4   5
Affiliations

Variations in Circulating Tumor Microenvironment-Associated Proteins in Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C Treatment

Benito Blanco Gómez et al. Int J Mol Sci. .

Abstract

Mitomycin C (MMC) is a widely employed chemotherapeutic agent, particularly in non-muscle invasive bladder cancer (NMIBC), where it functions by inducing DNA cross-linking and promoting tumor cell apoptosis. However, the tumor microenvironment (TME) significantly influences the therapeutic efficacy of MMC. Among the key regulators within the TME, the complement system and the coagulation pathway play a crucial role in modulating immune responses to cancer therapies, including MMC. This article explores the interaction between platinum nanoparticles (PtNPs) with human serum (HS) of NMIBC patients (T1 and Ta subtypes) at three different points: before the chemotherapy instillation of MMC (t0) and three (t3) and six months (t6) after the treatment with MMC. This novel nanoproteomic strategy allowed the identification of a TME proteomic signature associated with the response to MMC treatment. Importantly, two proteins involved in the immune response were found to be deregulated across all patients (T1 and Ta subtypes) during MMC treatment: prothrombin (F2) downregulated and complement component C7 (C7) upregulated. By understanding how these biomarker proteins interact with MMC treatment, novel therapeutic strategies can be developed to enhance treatment outcomes and overcome resistance in NMIBC.

Keywords: SWATH-MS; complement system; mitomycin C (MMC); non-muscle invasive bladder cancer (NMIBC); platinum nanoparticles (PtNPs); protein corona (PC); tumor microenvironment (TME).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Diagrammatic overview of the protocol for PC assembly on PtNPs (2.40 ± 0.30 nm), following ex vivo incubation with HS from n = 42 healthy controls (HCs) and n = 42 NMIBC patients. Samples were collected at baseline (t0, pre-treatment) and three (t3) and six months (t6) post-mitomycin C (MMC) instillation.
Figure 2
Figure 2
Flowchart depicting the general pretreatment, depletion with DDT, and alkylation with IAA of human serum samples before the incubation with PtNPs (2.40 ± 0.30 nm) for the PC formation.
Figure 3
Figure 3
Venn diagram depicting the overlap and subtype-specific differentially expressed serum proteins adsorbed onto PtNPs (2.40 ± 0.30 nm) after 30 min ex vivo incubation with HS from NMIBC patients of subtypes T1 and Ta (data for the T1 subtype are highlighted in blue color and for the Ta subtype in orange).
Figure 4
Figure 4
Venn diagram showing the number of shared and specific deregulated proteins identified in the PC-coated PtNPs (2.40 ± 0.30 nm) after their incubation (30 min) with HS samples from NMIBC patients of the T1 subtype (left) and Ta subtype (right) at different times (t0, t3, and t6).
Figure 5
Figure 5
Clusters found in the protein–protein interaction network map based on the STRING database, highlighting proteins associated with the immune response pathway. At the top, clusters with 13, 17, and 17 deregulated proteins related to the immune response pathway found in the T1 subtype at t0, t3, and t6, respectively, are shown. A total of 23, 12, and 22 proteins related to the immune response pathway were deregulated in the Ta subtype at times t0, t3, and t6, respectively (down).
Figure 6
Figure 6
Synthesis of citrate-coated PtNPs (2.40 ± 0.30 nm).
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Babjuk M., Burger M., Capoun O., Cohen D., Compérat E.M., Dominguez Escrig J.L., Gontero P., Liedberg F., Masson-Lecomte A., Mostafid A.H., et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ) Eur. Urol. 2022;81:75–94. doi: 10.1016/j.eururo.2021.08.010. - DOI - PubMed
    1. Jiang L.-J., Guo S.-B., Huang Z.-Y., Li X.-L., Jin X.-H., Huang W.-J., Tian X.-P. PHB promotes bladder cancer cell epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway. Pathol. Res. Pract. 2023;247:154536. doi: 10.1016/j.prp.2023.154536. - DOI - PubMed
    1. Jiang L.-J., Guo S.-B., Zhou Z.-H., Li Z.-Y., Zhou F.-J., Yu C.-P., Li M., Huang W.-J., Liu Z.-W., Tian X.-P. Snai2-mediated upregulation of NADSYN1 promotes bladder cancer progression by interacting with PHB. Clin. Transl. Med. 2024;14:e1555. doi: 10.1002/ctm2.1555. - DOI - PMC - PubMed
    1. Scilipoti P., Ślusarczyk A., Angelis M., Soria F., Pradere B., Krajewski W., D’Andrea D., Mari A., Giudice F., Pichler R., et al. European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. The Role of Mitomycin C in Intermediate-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur. Urol. Oncol. 2024;7:1293–1302. doi: 10.1016/j.euo.2024.06.005. - DOI - PubMed

LinkOut - more resources